Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: generic drug

Not-for-Profit to Offer 20 Generic Drugs in 2019 to Alleviate Shortages

Jilian Mincer  |  January 25, 2019

(Reuters)—A new not-for-profit supplier of generic drugs formed by a consortium of hospitals systems said it expects this year to be able to provide about 20 products to alleviate shortages of medicines used during surgeries and to treat life-threatening conditions, such as septic shock. Since the start-up of Civica Rx spearheaded by Intermountain Healthcare was…

Filed under:Drug Updates Tagged with:Drug shortagegeneric drugsIntermountain Healthcare

U.S. Hospital Systems Team Up to Launch Generic Drugmaker

Reuters Staff  |  January 18, 2018

NEW YORK (Reuters)—A group of four hospital systems plans to launch a not-for-profit generic drugmaker aimed at combating shortages and high costs of some generic drugs, which they blame on unscrupulous drug companies that hike prices. Intermountain Healthcare said on Thursday it was working with three other large U.S.-based hospital systems including Ascension, SSM Health…

Filed under:Drug Updates Tagged with:AscensionFDA-approved manufacturing companyfour hospital systemsIntermountain Healthcarenot-for-profit generic drugmakerSSM HealthTrinity Health

AmerisourceBergen Expects Tumbling Generic Drug Prices to Settle

Anuron Kumar Mitra and Tamara Mathias  |  November 3, 2017

(Reuters)—AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon’s possible entry into the industry. The drug distributor ended its fiscal year with a quarterly loss as it set aside $575 million for legal costs for a…

Filed under:Uncategorized Tagged with:AmerisourceBergen CorpAmerisourceBergen lawsuitlow generic drug prices

U.S. Tribal Patent Deal Could Impact Generic Drug Market

Jan Wolfe  |  September 12, 2017

(Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…

Filed under:Drug UpdatesLegal Updates Tagged with:Allergan Plc.generic competitiongeneric drugsLegalRestasis

U.S. House Panel Spotlights Use of FDA Rules to Slow Generic Drugs

Diane Bartz  |  July 28, 2017

WASHINGTON (Reuters)—Republican and Democratic lawmakers on Thursday discussed ways to prevent drugmakers from using rules developed to safeguard patients to instead block the sale of cheaper medicines. The focus at a hearing, held by members of the House Judiciary Committee’s antitrust subcommittee, was on the use by some brand name drug companies of a U.S….

Filed under:Drug Updates Tagged with:FDAFood and Drug Administrationgeneric drugmakersgeneric drugsgeneric pharmaceutical companiesREMSRisk Evaluation and Mitigation StrategyU.S. Food and Drug Administration

Generic Drug Group Sues to Block Maryland Price-Gouging Law

Nate Raymond  |  July 7, 2017

(Reuters)—The main U.S. trade group for generic pharmaceutical companies filed a lawsuit on Thursday seeking to block a recently adopted Maryland law that lets the state attorney general sue generic drugmakers that sharply raise prices. The Association for Accessible Medicines filed the lawsuit in federal court in Baltimore to seek an injunction that would block…

Filed under:Legal Updates Tagged with:Association for Accessible Medicinesgeneric pharmaceutical companieslawsuitMaryland Attorney General Brian FroshMaryland lawrising U.S. drug costs

U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System

Toni Clarke  |  June 21, 2017

WASHINGTON (Reuters)—The U.S. Food and Drug Administration moved on Wednesday to prevent pharmaceutical companies from “gaming” the system to block or delay entry of generic rivals. FDA Commissioner Scott Gottlieb said in a blog post that the agency plans to hold a public meeting on July 18 to identify ways pharmaceutical companies are using FDA…

Filed under:Drug UpdatesPractice SupportProfessional Topics Tagged with:generic competitionpharmaceutical companiesU.S. Food and Drug Administration

U.S. Could File Charges in Generic Drug Probe by Year-End

Reuters Staff  |  November 4, 2016

(Reuters)—U.S. prosecutors could file the first charges in their criminal investigation of generic drugmakers over suspected price collusion by the end of the year, Bloomberg reports. The antitrust investigation by the U.S. Department of Justice (DOJ) spans more than a dozen companies and about two dozen drugs, Bloomberg reports, citing people familiar with the matter….

Filed under:Drug Updates Tagged with:Department of Justicegeneric drugsLegal

Cephalon, U.S. States Reach $125 Million Settlement Over Generic Drugs

Sarah N. Lynch  |  August 6, 2016

WASHINGTON (Reuters)—Cephalon has reached a $125 million settlement with 48 states in connection with its alleged efforts to delay generic versions of its blockbuster sleep disorder drug modafinil (Provigil) from entering the market, New York Attorney General Eric Schneiderman said on Thursday. The settlement with Cephalon, now owned by Teva Pharmaceuticals, comes a little more…

Filed under:Drug UpdatesLegal Updates Tagged with:generic drugslawsuitLegalTeva Pharmaceuticals

EMA Flags Faulty Generic Drug Data, Backs Sales Halt

Reuters Staff  |  July 26, 2016

(Reuters)—The European Medicines Agency (EMA) recommended suspending sales of some generic drugs after a review found that data collected by a contract research company in India for their approval was unreliable. The EMA’s list included drugs made by some of the top generic drugmakers, including Teva Pharmaceutical Industries Ltd., Mylan NV and Novartis AG’s Sandoz….

Filed under:Drug Updates Tagged with:European Medicines Agencygeneric drugsRegulationTeva Pharmaceuticals

  • 1
  • 2
  • 3
  • …
  • 69
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences